Kymera Investor Day Presentation Deck

TCGA Oliner, et al. 2015 KYMERA Focus on Indications Where MDM2 Degradation Leads to Acute Apoptotic Response p53 WT in >50% of Tumors ● ● ● ● ● ● • AML ● ● Mesothelioma Melanoma DLBCL Prostate cancer ● Cholangiocarcinoma Cervical cancer Renal cell cancer Uveal melanoma Thyroid cancer Liposarcoma HCC Breast cancer ©2021 KYMERA THERAPEUTICS, INC. MOA-specific Sensitivity (Biomarker-based) ● ● AML Uveal Melanoma ● Lymphomas Others will be disclosed in upcoming medical meetings KYMERA KYMERA R&D DAY - December 16th, 2021 ● ● ● ● ● MDM2 Amplification Liposarcoma (87%) Sarcoma (19%) Glioblastoma multiforme (7%) Bladder (3%) Cholangiocarcinoma (3%) TCGA Donehower, et al. 2020 PAGE 83

View entire presentation